64.49

1.39% -0.91

After Hours: 64.49

Halozyme Therapeutics Inc (HALO)

Overview News Price History Option Chain Financials Why HALO Down? Discussions Forecast

Halozyme Therapeutics Inc stock is traded at $64.49, with a volume of 1.52M. It is down -1.39% in the last 24 hours and down -7.67% over the past month. Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Previous Close:

$65.40

Open:

$64.22

24h Volume:

1.52M

Relative Volume:

0.83

Market Cap:

$7.64B

Revenue:

$1.40B

Net Income/Loss:

$316.89M

P/E Ratio:

25.88

EPS:

2.4918

Net Cash Flow:

$644.59M

1W Performance:

+1.90%

1M Performance:

-7.67%

6M Performance:

-10.04%

1Y Performance:

+2.33%

1-Day Range:

$63.61

$65.65

1-Week Range:

$61.33

$66.00

52-Week Range:

$47.50

$82.22

Halozyme Therapeutics Inc Stock (HALO) Company Profile

Name

Halozyme Therapeutics Inc

Sector

Healthcare (1118)

Industry

Biotechnology (624)

Phone

(858) 794-8889

Address

12390 EL CAMINO REAL, SAN DIEGO, CA

Employee

423

Twitter

@halozymeinc

Next Earnings Date

2025-02-18

Latest SEC Filings

HALO's Discussions on Twitter

Compare HALO vs VRTX, REGN, ARGX, ALNY, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
HALO Halozyme Therapeutics Inc	64.49	7.64B	1.40B	316.89M	644.59M	2.4918
VRTX Vertex Pharmaceuticals Inc	438.71	111.45B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	761.85	80.54B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	746.42	46.32B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	318.85	42.29B	3.71B	313.75M	465.38M	2.2571
INSM Insmed Inc	162.43	35.01B	606.42M	-1.28B	-997.58M	-6.403

Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-04-25	Downgrade	Goldman	Neutral → Sell
Oct-14-25	Upgrade	Leerink Partners	Underperform → Market Perform
Aug-06-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jul-10-25	Resumed	Goldman	Neutral
May-14-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
May-13-25	Downgrade	Leerink Partners	Market Perform → Underperform
Oct-07-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Sep-19-24	Downgrade	JP Morgan	Overweight → Neutral
Jun-07-24	Downgrade	Piper Sandler	Overweight → Neutral
Feb-29-24	Initiated	TD Cowen	Outperform
Jul-24-23	Downgrade	Goldman	Buy → Neutral
Jul-24-23	Initiated	H.C. Wainwright	Buy
May-10-23	Upgrade	Piper Sandler	Neutral → Overweight
Mar-27-23	Resumed	Berenberg	Buy
Mar-16-23	Downgrade	SVB Securities	Outperform → Market Perform
Dec-21-22	Resumed	Morgan Stanley	Overweight
Nov-28-22	Initiated	Wells Fargo	Overweight
Sep-09-22	Initiated	Morgan Stanley	Overweight
May-23-22	Initiated	SVB Leerink	Outperform
Jun-14-21	Initiated	Evercore ISI	Outperform
May-17-21	Initiated	SVB Leerink	Outperform
May-11-21	Downgrade	Piper Sandler	Overweight → Neutral
Jan-21-21	Reiterated	The Benchmark Company	Buy
Dec-17-20	Initiated	Berenberg	Buy
Sep-14-20	Resumed	JP Morgan	Overweight
Jul-01-20	Initiated	The Benchmark Company	Buy
Feb-05-20	Upgrade	Piper Sandler	Neutral → Overweight
Jan-09-20	Upgrade	BMO Capital Markets	Market Perform → Outperform
Jan-08-20	Initiated	Goldman	Buy
Nov-05-19	Upgrade	Barclays	Underweight → Equal Weight
Oct-19-18	Resumed	Piper Jaffray	Neutral
May-11-18	Downgrade	Barclays	Equal Weight → Underweight
Jan-24-18	Initiated	Goldman	Neutral
Oct-16-17	Reiterated	Piper Jaffray	Overweight
Jan-06-17	Downgrade	Citigroup	Buy → Neutral
Nov-03-16	Initiated	Deutsche Bank	Buy
Dec-04-15	Initiated	Wells Fargo	Outperform
Nov-18-15	Initiated	Citigroup	Buy
Sep-22-15	Initiated	Barclays	Overweight
Jun-22-15	Reiterated	JP Morgan	Overweight
Mar-03-15	Reiterated	UBS	Buy
Feb-18-15	Reiterated	MLV & Co	Buy
Jan-08-15	Reiterated	MLV & Co	Buy

View All

Halozyme Therapeutics Inc Stock (HALO) Latest News

05:09 AM

How The Investment Story Is Shifting For Halozyme Therapeutics (HALO) After Recent Analyst Calls - Yahoo Finance

05:09 AM

Apr 03, 2026

Hedge Fund and Insider Trading News: Warren Buffett, George Soros, Steve Cohen, Ken Griffin, Brevan Howard, Tudor Investment Corp, L.B. Foster (FSTR), Halozyme Therapeutics Inc (HALO), and More - insidermonkey.com

Apr 03, 2026

Halozyme Therapeutics (HALO) appoints interim CFO amid growth plans - MSN

Apr 03, 2026

Tema Etfs LLC Invests $1.7M in Halozyme Therapeutics - National Today

Apr 03, 2026

Tema Etfs LLC Makes New $1.70 Million Investment in Halozyme Therapeutics, Inc. $HALO - MarketBeat

Apr 03, 2026

Apr 02, 2026

Halozyme Therapeutics CEO sells $2.59 million in stock By Investing.com - Investing.com Canada

Apr 02, 2026

Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) CEO Sells 20,000 Shares of Stock - MarketBeat

Apr 02, 2026

Halozyme (NASDAQ: HALO) grants 10,000 RSUs to interim CFO Ramsay - Stock Titan

Apr 02, 2026

Halozyme (NASDAQ: HALO) CEO exercises 40k options, sells 40k shares - Stock Titan

Apr 02, 2026

HALO Stock Price, Quote & Chart | HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - ChartMill

Apr 02, 2026

Mar 31, 2026

HALOZYME THERAPEUTICS Accounts Payable & Accrued Expense: $1 - GuruFocus

Mar 31, 2026

Is Halozyme Therapeutics (HALO) Pricing Reflect Its Potential After Recent Share Price Pullback - Sahm

Mar 31, 2026

Mar 30, 2026

Halozyme Therapeutics Experiences Revision in Stock Evaluation Amid Market Volatility - Markets Mojo

Mar 30, 2026

Mar 29, 2026

Halozyme Therapeutics (HALO) Appoints Interim CFO Amid Growth Plans - Insider Monkey

Mar 29, 2026

Halozyme to Report Second Quarter 2025 Financial and Operating Results - Quantisnow

Mar 29, 2026

Record revenue and royalties fail to lift Halozyme Therapeutics stock amid sustained technical weakness - Traders Union

Mar 29, 2026

Sell Signal: Will Halozyme Therapeutics Inc announce a stock split2026 Sentiment & Proven Capital Preservation Methods - baoquankhu1.vn

Mar 29, 2026

Assenagon Asset Management Acquires Stake in Halozyme Therapeutics - National Today

Mar 29, 2026

Assenagon Asset Management S.A. Takes Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat

Mar 29, 2026

Mar 28, 2026

Why is Halozyme Therapeutics (HALO) down 13.1% since last earnings report? - MSN

Mar 28, 2026

Mar 27, 2026

HALO (Halozyme Therapeutics) Cash Receipts from Tax Refunds - GuruFocus

Mar 27, 2026

Halozyme Therapeutics prices $1.3 billion convertible notes - MSN

Mar 27, 2026

Vanguard realignment reports zero Halozyme holdings (NASDAQ: HALO) - Stock Titan

Mar 27, 2026

A Look At Halozyme Therapeutics (HALO) Valuation After Mixed Quarterly Earnings And Guidance - Sahm

Mar 27, 2026

Mar 26, 2026

Is Halozyme’s Interim CFO Appointment Shaping The ENHANZE Royalty Story For Halozyme Therapeutics (HALO)? - simplywall.st

Mar 26, 2026

Mar 25, 2026

Unpacking Q4 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks - Yahoo Finance

Mar 25, 2026

Mar 24, 2026

Halozyme declines after Q4 bottom line miss, reiterates 2026 guidance - MSN

Mar 24, 2026

Congress Asset Management Co. Cuts Stake in Halozyme Therapeutics - National Today

Mar 24, 2026

Congress Asset Management Co. Cuts Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat

Mar 24, 2026

Mar 23, 2026

Interim CFO at Halozyme (NASDAQ: HALO) files initial Form 3 ownership - Stock Titan

Mar 23, 2026